Skip to main content
NASDAQ:CNTB

Connect Biopharma Competitors

$16.22
-0.19 (-1.16 %)
(As of 05/18/2021 03:45 AM ET)
Add
Compare
Today's Range
$15.90
$16.55
50-Day Range
$14.43
$18.50
52-Week Range
$14.27
$23.29
Volume548 shs
Average Volume143,122 shs
Market Capitalization$932.71 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Connect Biopharma (NASDAQ:CNTB) Vs. SANA, RXRX, NUVB, SEER, IBRX, and IMCR

Should you be buying CNTB stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Connect Biopharma, including Sana Biotechnology (SANA), Recursion Pharmaceuticals (RXRX), Nuvation Bio (NUVB), Seer (SEER), ImmunityBio (IBRX), and Immunocore (IMCR).

Sana Biotechnology (NASDAQ:SANA) and Connect Biopharma (NASDAQ:CNTB) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk.

Profitability

This table compares Sana Biotechnology and Connect Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sana BiotechnologyN/AN/AN/A
Connect BiopharmaN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and price targets for Sana Biotechnology and Connect Biopharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sana Biotechnology02202.50
Connect Biopharma00303.00

Sana Biotechnology currently has a consensus price target of $40.00, indicating a potential upside of 106.40%. Connect Biopharma has a consensus price target of $29.50, indicating a potential upside of 81.87%. Given Sana Biotechnology's higher possible upside, research analysts clearly believe Sana Biotechnology is more favorable than Connect Biopharma.

Earnings & Valuation

This table compares Sana Biotechnology and Connect Biopharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sana BiotechnologyN/AN/AN/AN/AN/A
Connect BiopharmaN/AN/AN/AN/AN/A

Summary

Connect Biopharma beats Sana Biotechnology on 2 of the 3 factors compared between the two stocks.

Connect Biopharma (NASDAQ:CNTB) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Profitability

This table compares Connect Biopharma and Recursion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Connect BiopharmaN/AN/AN/A
Recursion PharmaceuticalsN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Connect Biopharma and Recursion Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Connect Biopharma00303.00
Recursion Pharmaceuticals02302.60

Connect Biopharma currently has a consensus target price of $29.50, indicating a potential upside of 81.87%. Recursion Pharmaceuticals has a consensus target price of $33.20, indicating a potential upside of 48.21%. Given Connect Biopharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Connect Biopharma is more favorable than Recursion Pharmaceuticals.

Valuation and Earnings

This table compares Connect Biopharma and Recursion Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Connect BiopharmaN/AN/AN/AN/AN/A
Recursion PharmaceuticalsN/AN/AN/AN/AN/A

Summary

Connect Biopharma beats Recursion Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Connect Biopharma (NASDAQ:CNTB) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Profitability

This table compares Connect Biopharma and Nuvation Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Connect BiopharmaN/AN/AN/A
Nuvation BioN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Connect Biopharma and Nuvation Bio, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Connect Biopharma00303.00
Nuvation Bio00603.00

Connect Biopharma currently has a consensus target price of $29.50, indicating a potential upside of 81.87%. Nuvation Bio has a consensus target price of $17.40, indicating a potential upside of 52.90%. Given Connect Biopharma's higher possible upside, equities analysts plainly believe Connect Biopharma is more favorable than Nuvation Bio.

Valuation and Earnings

This table compares Connect Biopharma and Nuvation Bio's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Connect BiopharmaN/AN/AN/AN/AN/A
Nuvation BioN/AN/AN/AN/AN/A

Connect Biopharma (NASDAQ:CNTB) and Seer (NASDAQ:SEER) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Profitability

This table compares Connect Biopharma and Seer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Connect BiopharmaN/AN/AN/A
SeerN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Connect Biopharma and Seer, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Connect Biopharma00303.00
Seer02202.50

Connect Biopharma currently has a consensus target price of $29.50, indicating a potential upside of 81.87%. Seer has a consensus target price of $66.3333, indicating a potential upside of 112.47%. Given Seer's higher possible upside, analysts plainly believe Seer is more favorable than Connect Biopharma.

Valuation and Earnings

This table compares Connect Biopharma and Seer's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Connect BiopharmaN/AN/AN/AN/AN/A
SeerN/AN/AN/AN/AN/A

Summary

Connect Biopharma beats Seer on 2 of the 3 factors compared between the two stocks.

Connect Biopharma (NASDAQ:CNTB) and ImmunityBio (NASDAQ:IBRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Profitability

This table compares Connect Biopharma and ImmunityBio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Connect BiopharmaN/AN/AN/A
ImmunityBioN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Connect Biopharma and ImmunityBio, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Connect Biopharma00303.00
ImmunityBio00103.00

Connect Biopharma currently has a consensus target price of $29.50, indicating a potential upside of 81.87%. ImmunityBio has a consensus target price of $25.00, indicating a potential upside of 49.16%. Given Connect Biopharma's higher possible upside, equities analysts plainly believe Connect Biopharma is more favorable than ImmunityBio.

Valuation and Earnings

This table compares Connect Biopharma and ImmunityBio's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Connect BiopharmaN/AN/AN/AN/AN/A
ImmunityBioN/AN/AN/AN/AN/A

Summary

Connect Biopharma beats ImmunityBio on 2 of the 2 factors compared between the two stocks.

Connect Biopharma (NASDAQ:CNTB) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Profitability

This table compares Connect Biopharma and Immunocore's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Connect BiopharmaN/AN/AN/A
ImmunocoreN/AN/AN/A

Valuation and Earnings

This table compares Connect Biopharma and Immunocore's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Connect BiopharmaN/AN/AN/AN/AN/A
ImmunocoreN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Connect Biopharma and Immunocore, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Connect Biopharma00303.00
Immunocore01202.67

Connect Biopharma currently has a consensus target price of $29.50, indicating a potential upside of 81.87%. Immunocore has a consensus target price of $54.3333, indicating a potential upside of 45.24%. Given Connect Biopharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Connect Biopharma is more favorable than Immunocore.

Summary

Connect Biopharma beats Immunocore on 3 of the 3 factors compared between the two stocks.


Connect Biopharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Sana Biotechnology logo
SANA
Sana Biotechnology
1.2$20.31-5.6%$3.60 billionN/A0.00
RXRX
Recursion Pharmaceuticals
1.5$23.11-5.5%$3.54 billionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Nuvation Bio logo
NUVB
Nuvation Bio
2.1$11.75-1.4%$2.18 billionN/A0.00Analyst Upgrade
News Coverage
SEER
Seer
1.1$32.44-5.0%$1.88 billionN/A0.00Analyst Report
IBRX
ImmunityBio
1.7$16.69-0.6%$1.81 billionN/A0.00News Coverage
Gap Up
Immunocore logo
IMCR
Immunocore
1.3$37.02-1.3%$1.62 billionN/A0.00Analyst Revision
News Coverage
Gap Down
BioAtla logo
BCAB
BioAtla
1.7$46.17-0.8%$1.54 billionN/A0.00Earnings Announcement
EWTX
Edgewise Therapeutics
1.8$27.43-1.9%$1.28 billionN/A0.00
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.4$30.38-6.6%$1.23 billionN/A0.00
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
2.0$26.59-2.9%$1.15 billionN/A0.00
KNTE
Kinnate Biopharma
1.7$26.10-10.9%$1.01 billionN/A0.00News Coverage
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$28.49-0.0%$994.39 millionN/A0.00Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Down
STEM
Stem
0.0$20.05-3.0%$932.59 millionN/A0.00Gap Up
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$24.74-0.8%$875.42 millionN/A0.00Earnings Announcement
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.4$12.14-9.0%$815.97 millionN/A0.00Earnings Announcement
News Coverage
Pharming Group logo
PHAR
Pharming Group
0.0$12.11-0.0%$776.60 millionN/A0.00
FDMT
4D Molecular Therapeutics
1.3$27.71-3.0%$717.80 millionN/A0.00Earnings Announcement
High Trading Volume
Vor Biopharma logo
VOR
Vor Biopharma
1.5$20.37-6.0%$711.08 millionN/A0.00
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.3$19.35-4.0%$674.61 millionN/A0.00Analyst Report
Analyst Revision
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.5$21.50-3.7%$659.09 millionN/A0.00Gap Up
FNCH
Finch Therapeutics Group
2.0$13.02-7.5%$613.83 millionN/A0.00Earnings Announcement
VACC
Vaccitech
0.3$16.93-0.4%$579.09 millionN/A0.00Gap Up
Inventiva logo
IVA
Inventiva
1.4$14.75-3.7%$569.79 millionN/A0.00
ACHL
Achilles Therapeutics
1.6$13.33-0.9%$546.37 millionN/A0.00
Nanobiotix logo
NBTX
Nanobiotix
0.9$15.65-1.2%$521.77 millionN/A0.00
VECT
VectivBio
1.6$14.95-7.9%$508.52 millionN/A0.00Quiet Period Expiration
Gap Down
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$11.18-1.2%$475.14 millionN/A0.00
Landos Biopharma logo
LABP
Landos Biopharma
1.5$12.31-5.2%$468.18 millionN/A0.00Earnings Announcement
News Coverage
Gap Down
BMEA
Biomea Fusion
1.7$15.84-1.3%$461.44 millionN/A0.00Analyst Report
News Coverage
SGTX
Sigilon Therapeutics
1.4$13.65-3.6%$430.38 millionN/A0.00
RAIN
Rain Therapeutics
1.3$17.23-7.3%$414.73 millionN/A0.00Analyst Report
Insider Buying
News Coverage
MIGI
Mawson Infrastructure Group
0.0$0.85-4.7%$413.38 millionN/A0.00Upcoming Earnings
Gap Down
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
1.7$16.59-1.3%$411.30 millionN/A0.00Gap Down
NexImmune logo
NEXI
NexImmune
1.7$18.12-0.8%$409.19 millionN/A0.00News Coverage
Angion Biomedica logo
ANGN
Angion Biomedica
1.6$13.82-1.7%$407.47 millionN/A0.00Earnings Announcement
News Coverage
PRTG
Portage Biotech
0.0$27.61-4.3%$333.61 millionN/A0.00
HOWL
Werewolf Therapeutics
0.3$11.87-0.8%$329.64 millionN/A0.00
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
1.9$9.20-1.1%$278.35 millionN/A0.00Earnings Announcement
Analyst Downgrade
Analyst Revision
Gap Down
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.5$6.78-4.4%$275.52 millionN/A-2.68
IMPL
Impel NeuroPharma
1.3$14.90-6.8%$269.67 millionN/A0.00Analyst Report
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$4.55-3.5%$240.81 millionN/A-2.42Earnings Announcement
Analyst Upgrade
VINC
Vincerx Pharma
1.0$16.85-2.6%$229.62 millionN/A0.00Gap Down
RPHM
Reneo Pharmaceuticals
2.0$7.90-1.5%$191.27 millionN/A0.00Quiet Period Expiration
Annovis Bio logo
ANVS
Annovis Bio
1.7$26.94-1.9%$190.70 millionN/A0.00
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
1.8$6.77-3.5%$162.61 millionN/A0.00Earnings Announcement
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$7.50-0.5%$144.53 millionN/A0.00
LBPH
Longboard Pharmaceuticals
1.9$9.02-3.0%$118.88 millionN/A0.00
EVAX
Evaxion Biotech A/S
1.7$6.77-8.7%$118.65 millionN/A0.00Gap Up
GANX
Gain Therapeutics
1.7$9.79-1.8%$116.24 millionN/A0.00News Coverage
LGVN
Longeveron
0.0$5.29-0.2%$100.28 millionN/A0.00
This page was last updated on 5/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.